[HTML][HTML] Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from …

LQM Chow, R Haddad, S Gupta, A Mahipal… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
LQM Chow, R Haddad, S Gupta, A Mahipal, R Mehra, M Tahara, R Berger, JP Eder
Journal of Clinical Oncology, 2016ncbi.nlm.nih.gov
Purpose Treatment with pembrolizumab, an anti–programmed death-1 antibody, at 10
mg/kg administered once every 2 weeks, displayed durable antitumor activity in
programmed death-ligand 1 (PD-L1)–positive recurrent and/or metastatic (R/M) head and
neck squamous cell carcinoma (HNSCC) in the KEYNOTE-012 trial. Results from the
expansion cohort, in which patients with HNSCC, irrespective of biomarker status, received
a fixed dose of pembrolizumab at a less frequent dosing schedule, are reported.
Abstract
Purpose
Treatment with pembrolizumab, an anti–programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1)–positive recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-012 trial. Results from the expansion cohort, in which patients with HNSCC, irrespective of biomarker status, received a fixed dose of pembrolizumab at a less frequent dosing schedule, are reported.
ncbi.nlm.nih.gov